Key Segmentation
By Technology
-
Next-Generation Sequencing (NGS)
-
Whole Exome Sequencing (WES)
-
Whole Genome Sequencing (WGS)
-
PCR-Based Testing
-
Chromosomal Microarray Analysis
-
Sanger Sequencing
-
Karyotyping
-
Others
By Specialty
-
Molecular Genetic Tests
-
Chromosomal Genetic Tests
-
Biochemical Genetic Tests
By Disease Type
-
Immunological Disorders
-
Endocrine & Metabolism Diseases
-
Cardiovascular Disorders
-
Neurological Disorders
-
Hematology & Oncology
-
Musculoskeletal Disorders
-
Others
By End-Use
-
Research Laboratories & CROs
-
Hospitals & Clinics
-
Diagnostic Laboratories
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
North America dominated the Rare Disease Genetic Testing Market in 2025, accounting for approximately 38% of global market revenue.
The Next-Generation Sequencing (NGS) segment dominated the Rare Disease Genetic Testing Market in 2025, accounting for approximately 33.9% of technology segment revenue.
Growing global prevalence of rare disease recognition and rapidly advancing next-generation sequencing technologies enabling scalable, cost-effective genetic testing that is improving rare disease diagnosis rates and supporting treatment access.
The Rare Disease Genetic Testing Market was valued at USD 1.40 billion in 2025.
The Rare Disease Genetic Testing Market is expected to grow at a CAGR of 15.36% from 2026 to 2035.